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Abstract
Background: Endocrine resistance is a major obstacle to optimal treatment effect in breast cancer. Some genetic
markers have been proposed to predict response to aromatase inhibitors (AIs) but the data is insufficient. The aim
of the study was to find new genetic treatment predictive markers of AIs.
Methods: The ongoing population-based BC-blood study in Lund, Sweden includes women with primary breast
cancer. This paper is based on AI-treated patients with estrogen receptor positive tumors who underwent breast
cancer surgery in 2002–2008. First, an exploratory analysis of 1931 SNPs in 227 genes involved in absorption,
distribution, metabolism, and elimination of multiple medications, using DMET™ chips, was conducted in a subset
of the cohort with last follow-up in December 31st 2011 (13 cases, 11 controls). Second, selected SNPs from the first
analysis were re-analyzed concerning risk for early breast cancer events in the extended cohort of 201
AI-treated with last follow-up in June 30th 2014. Clinical data were obtained from medical records and
population registries.
Results: Only CYP1A2 rs762551 C-allele was significantly associated with increased risk for early events in the
24 patients (P = 0.0007) and in the extended cohort, adjusted Hazard ratio (HR) 2.22 (95 % CI 1.03–4.80).
However, the main prognostic impact was found within five years, adjusted HR 7.88 (95 % CI
2.13–29.19). The impact of the CYP1A2 rs762551 C-allele was modified by a functional polymorphism in the
regulator gene AhR Arg554Lys (G > A). Compared to patients who were homozygous for the major allele in
both genes (CYP1A2 A/A and AhR G/G), a 9-fold risk for early events was found in patients who had at least
one minor allele in both genes, adjusted HR 8.95 (95 % CI 2.55–31.35), whereas patients with at least one
minor allele in either but not both genes had a 3-fold risk for early events, adjusted HR 2.81 (95 % CI 1.07–7.33). The
impact of CYP1A2 rs762551 C-allele was also modified by the CYP19A1 rs4646 C/C, adjusted HR 3.39 (95 % CI 1.60–7.16)
for this combination. This association was strongest within the first five years, adjusted HR 10.42 (95 % CI 3.45–31.51).
Conclusion: CYP1A2 rs762551 was identified as a new potential predictive marker for early breast cancer events in
AI-treated breast cancer patients. Moreover, combined genotypes of CYP1A2 rs762551 and CYP19A1 rs4646 or AhR
Arg554Lys could further improve prediction of early AI-treatment response. If confirmed, these results may provide a
way to more personalized medicine.
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Background
Breast cancer is one of the leading causes of cancer mor-
bidity and mortality among women worldwide [1]. The
majority of breast cancer patients have tumors that ex-
press hormone receptors [2, 3] and can thus be offered
endocrine therapy such as tamoxifen and aromatase in-
hibitors (AIs). However, endocrine resistance is a major
obstacle to optimal treatment effect [4]. Several genetic
markers for tamoxifen response have been proposed, al-
though no consensus has yet been reached [5–11]. For
AIs, data on genetic markers are sparse [10–13]. The re-
sponse rates to AIs vary between 35 and 70 % in the
neoadjuvant setting [4, 14, 15] and may be lower in ad-
vanced disease [16]. By identifying mechanisms of resist-
ance as well as treatment predictive factors, patients
may be offered more effective personalized medicine and
be spared side-effects of ineffective treatment [17].
Only a few studies have investigated the association
between polymorphisms in Cytochrome P450 (CYP)
CYP19A1 (aromatase) and disease-free survival in breast
cancer [10, 18, 19]. There are currently only a few stud-
ies published with a proposed polymorphism for predict-
ing AI response in the adjuvant setting, and these have
contradictory results [11, 13]. Some studies have investi-
gated the impact of CYP19A1 polymorphisms on
treatment response in the metastatic- [20] and in the
neoadjuvant settings [21, 22]. However, the results have
been inconsistent. Therefore, it is currently unknown
whether single nucleotide polymorphisms (SNPs) in
CYP19A1 are associated with a risk of early events in pa-
tients treated with AI as first line treatment.
The formation and metabolism of estrogens in the
steroidal sex hormone metabolism is complex and in-
volves several enzymes. In addition to CYP19A1, some
examples include CYP1A1, CYP1A2, COMT, and
CYP3A4 [23]. Several of these enzymes are also involved
in the metabolism of AIs [24, 25]. Furthermore, AIs
interfere with some of these enzymes; letrozole has been
shown to inhibit CYP2A6 and CYP2C19 in vitro [26],
anastrozole has been shown to inhibit CYP1A2,
CYP2C9, and CYP3A in vitro [27], and exemestane has
been shown to be metabolized by CYP4A11 and
CYP1A1/2 in vitro [28]. Polymorphisms in the corre-
sponding genes may be a mechanism behind primary
(de novo) resistance of AI as estrogens are known risk
factors for recurrence of breast cancer and the enzymes
that metabolize estrogens are tightly linked to AI metab-
olism. Two of these genes involved in estrogen metabol-
ism, CYP1A1 and CYP1A2, share a common promoter
[29] and are under regulatory control of the aryl hydro-
carbon receptor (AhR) [30]. These genes may therefore
be of interest to study in relation to AI response.
To find new markers beyond the candidate genes for
AI resistance, it might be useful to expand the search to
other known genes involved in Absorption, Distribution,
Metabolism, and Elimination (ADME-related genes).
High-throughput, drug metabolism enzymes and trans-
porters (DMET™) chips genotype several SNPs at the
same time [31]. The Affymetrix DMET Plus Premier
Pack includes 1931 SNPs in 227 genes in ADME-related
genes on a single array. We hypothesized that SNPs in
the aromatase gene CYP19A1 and SNPs in other genes
for drug and estrogen metabolism may be used as treat-
ment predictive markers for adjuvant treatment with AI
in primary breast cancer patients. The aim of the study
was: 1) to perform an exploratory analysis using the
DMET™ chip to find new treatment predictive markers
in a subset of the cohort and 2) to examine these poten-
tial markers with a special focus on CYP19A1 in relation
to a risk for early events in the extended cohort of
AI-treated breast cancer patients.
Methods
Study population
Women diagnosed with a primary breast cancer at the
Skåne University Hospital in Lund, Sweden were invited
preoperatively to participate in an ongoing prospective
population-based cohort—the BC-blood study. Patients
with a prior history of another cancer diagnosis within
the last ten years were not enrolled. The overall aims of
the BC-blood study are to elucidate factors that may
have prognostic or predictive value. This paper is based
on data collected from 634 primary breast cancer pa-
tients between October 2002 and October 2008. Patients
were followed from inclusion to the first breast cancer
event or distant metastasis, respectively, and patients
without events were censored at the last follow-up or
death prior to July 1st 2014. As previously described, the
follow-up rates of the patients were high [32]. During
the time the cohort was compiled, 1090 patients went
through breast cancer surgery and approximately 58 %
of these patients were included [33]. A lack of research
nurses explains most of the patients who were missed
and approximately 5 % of the patients were missed due
to unverified diagnosis at the time of surgery. Written
informed consent was obtained from all patients, and
the study was approved by the ethics committee of Lund
University (Dnr LU75-02, LU37-08, and LU658-09).
Breast cancer events included ipsilateral, contralat-
eral, axillary lymph node, and distant metastases. In-
formation concerning breast cancer events was
obtained from patient charts, pathology reports, and
the Regional Tumor Registry. The date of death was
obtained from the Swedish Population Registry. The
first breast cancer event of any type was considered
the primary endpoint, and distant metastasis was con-
sidered a secondary endpoint. Breast cancer treatment
was prescribed according to the standard of care at
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Skåne University hospital. Information regarding the
type of adjuvant treatment was collected from patient
charts and questionnaires. Treatment data were regis-
tered up to the last follow-up prior to any event.
Data on tumor size, histological type and grade, and
number of involved axillary lymph nodes were ob-
tained from each patient’s pathology report. The tu-
mors were analyzed at the Department of Pathology
at Lund University Hospital. Estrogen receptor (ER)
and progesterone receptor (PgR) status were deter-
mined as previously described [5, 34]. The patients
completed questionnaires preoperatively and at mul-
tiple times postoperatively. The questionnaires in-
cluded questions such as reproductive history, use of
exogenous hormones, smoking history, and any medi-
cations used during the past week as previously de-
scribed [35]. During the preoperative visit, a research
nurse collected blood samples for genotyping. The
blood was collected and centrifuged and the samples
were frozen at −80 ° C within two hours.
Genotyping
Genomic deoxyribonucleic acid (DNA) was extracted
from the patients’ leukocyte portion of frozen peripheral
blood using the Wizard Genomic DNA Purification Kit
(Promega, Madison, USA) or Quickgene-610 L and
Quickgene-810 (Fujifilm life science, Science imaging
AB, Scandinavia). The samples were then genotyped
using the DMET™ (Drug Metabolizing Enzymes and
Transporters) Plus Premier Pack, which is a microarray
assay developed by Affymetrix (Santa Clara, CA, USA),
according to the manufacturer’s instructions. The DMET™
experimental analysis was performed at SCIBLU Genomics
at Lund University.
Genotyping was also performed at the Region Skåne
Competence Centre (RSKC Malmö), Skåne University
Hospital, Malmö, Sweden. The CYP19A1 SNPs rs700518,
rs4646, Aro1 (rs4775936), Aro2 (rs10459592), and two
functional AhR SNPs Arg554Lys (rs2066853) and
Val570Ile (rs4986826) were analyzed with matrix-assisted
laser desorption/ionization time-of-flight mass spectrom-
etry on a Sequenom MassARRAY® platform (Sequenom,
San Diego, CA, USA), using iPLEX reagents according to
the manufacturers’ protocol. The Sequenom MassAR-
RAY® software was used for multiplex SNP analysis de-
sign. The rs700518 SNP was not successfully genotyped.
The rs10046 SNP and the CYP1A2*1 F (rs762551) SNP
were genotyped using a Taqman SNP allelic discrimin-
ation assay in 384-well format on an ABI PRISM 7900
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Over 10 % of the samples were run in
duplicates with a concordance of 100 %.
There were 19 patients not successfully genotyped for
the CYP1A2*1 F (rs762551) SNP using TaqMan. For 16
of these patients, rs762551 genotypes were available
from DNA sequencing from a previous study [18]. The
concordance rate between the two methods was 99.8 %.
Haplotypes of CYP19A1 were constructed by cross-
tabulation of the genotypes of the CYP19A1 SNPs. This
resulted in nine haplotypes. Linkage disequilibrium (LD)
was observed between rs4646 and rs10046 (r = 0.68), and
between rs10046 and Aro1 (r = 0.90), as well as between
Aro1 and Aro2 (r = 0.79). Therefore, the 14 missing
genotypes for rs10046 could be imputed. The minor
allele was defined according to the Database of Single
Nucleotide Polymorphisms (dbSNP) [36].
Data analyses
The analyses of data from the DMET™ chip were per-
formed using the DMET™ console software. The samples
with QC call rates ≥99 % were considered for further
analyses. The analysis included 13 patients with breast
cancer events who had been treated with AI but not
with chemotherapy prior to the event by December 31st
2011 (n = 13). The controls were 11 AI-treated patients
without chemotherapy or tamoxifen and without recur-
rence who had a follow-up time of at least five years
with last follow-up December 31st 2011. Fisher’s exact test
was used, and to make allowances for multiple testing, a
P-value < 0.005 was considered significant. This P-value
allows for 0.5 % of the findings to be false positive.
Statistical survival analyses of the extended cohort
were performed with IBM SPSS Statistics, version 19.0
(IBM Corp. Armonk, NY, USA). A flowchart of patients
included in the final survival analyses is presented in
Fig. 1. After exclusion, 201 AI-treated patients were in-
cluded in the analyses. In total, 32 patients were diag-
nosed with some type of breast cancer event during the
11-year follow-up period. Of these, 22 presented with
distant metastases. A Kaplan-Meier LogRank test was
used for univariable analyses of the risk of early events
in relation to the different genotypes, haplotypes, and
diplotypes of the SNPs. Since few patients had an inva-
sive tumor size ≥51 mm or muscular or skin involve-
ment, these patients were combined with the patients
with invasive tumor sizes between 21 and 50 mm in the
multivariable analyses. Regular smokers and occasional
smokers were classified as current smokers. Cox regres-
sion was used to calculate Hazard Ratios (HRs) in rela-
tion to the SNPs after adjusting for age (linear), invasive
tumor size (<21 mm versus ≥21 mm or skin or muscular
involvement independent of size), any axillary lymph
node involvement (yes/no), histological grade III (yes/no),
preoperative smoking status (yes/no), body mass index
(BMI) ≥25 kg/m2 (yes/no) radiation therapy (yes/no),
chemotherapy (yes/no), and tamoxifen therapy (yes/no). A
P-value < 0.05 was considered significant. All P-values
were two-tailed. Nominal P-values are presented without
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adjustments for multiple testing since this is an explora-
tory study [37]. A prior power calculation assuming a
study with 200 patients; 50 % of the patients had a major
allele and an accrual interval of 6 years with additional
follow-up after the accrual interval of 4 years, showed that
the study could detect true HRs of failure for patients
homozygous for the major allele relative to patients with
variant alleles of 0.603 or 1.824 with 80 % power and a
type 1 error probability of 0.05 [38]. The study is based on
the REMARK (Reporting Recommendations for Tumor
Marker Prognostic Studies) criteria [39].
Results
Patient characteristics, tumor characteristics, and AI
treatment
Patient and tumor characteristics of the patients are
presented in Tables 1 and 2, respectively. There were no
substantial differences in the characteristics between the
AI-treated patients in the extended cohort and the pa-
tients analyzed with the DMET™ chip other than age and
height. The distribution of AIs was as follows: anastrozole
67.2 %, letrozole 26.4 %, exemestane 5.0 %, anastrozole and
letrozole in sequence 1.0 %, and AI type missing 0.5 %.
501 patients with ER+ tumors
42 patients excluded due to
preoperative treatment 
14 patients excluded due to
carcinoma in situ 
2 patients excluded due to metastatic
spread within 3 months of inclusion
2 patients excluded due to missing
data regarding ER-status
73 patients with ER-tumors were 
excluded
201 patients ever treated with AI
160 patients treated with AI but not with 
chemotherapy




1090 patients diagnosed with breast cancer in 
Lund between 2002 and 2008
DMETTM chip
13 patients ever treated with AI but
with not chemotherapy
11 patients treated with AI but not
with chemotherapy or tamoxifen
CYP1A2 genotype
A/A   97
A/C   90




A/A            2 9
A/C            9 1
C/C            2 1
Missing 0 0 
634 patients included in the cohort between 
2002 and 2008
Fig. 1 Flowchart illustrating patients included and excluded in the different analyses
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DMET™ analysis and selection of SNPs for further analyses
Of the 1931 SNPs, 1911 were successfully genotyped.
Only the CYP1A2*1F rs762551 C-allele was significantly
associated with increased risk for early events among
the 24 AI-treated patients (P = 0.0007). The CYP1A2
rs762551 was thus elected for analyses in the ex-
tended cohort. The CYP19A1 SNPs were not signifi-
cantly associated with survival in the analyses of the
Table 1 Patient characteristics of the AI-treated patients with ER+ tumors included in the DMET™ chip analysis and the extended
cohort
Patients included in the analysis of the
DMET™ chip
Patients in the extended cohort included in the
survival analyses
n = 24 n = 201
Median (IQR) or % Missing Median (IQR) or % Missing
Age at diagnosis, yrs 67.7 (60.0–72.7) 0 60.9 (54.4–66.4) 0
Weight, kgs 70.0 (61.7–82.10) 0 70.0 (64.0–79.0) 2
Height, m 1.64 (1.58–1.68) 0 1.66 (1.62–1.70) 0
BMI, kgs/m2 26.6 (23.6–30.6) 0 25.2 (23.2–28.8) 2
Age at menarche, yrs 14.0 (13.0–14.0) 0 13.0 (12.0–14.0) 0
Parous, % 87.5 % 0 85.1 % 0
Age at first full-term pregnancy, yrsa 23.5 (21.0–26.8) 3 24.0 (22.0–27.0) 31
Ever use of oral contraceptives, % 62.5 % 0 70.6 % 0
Ever use of hormone therapy, % 45.8 % 0 54.0 % 1
Current smoker prior to surgery, % 20.8 % 0 17.4 % 0
Alcohol abstainers 16.9 % 0 10.0 % 1
Preoperative daily coffee consumption 2 + cups/day 75.0 % 0 83.5 % 1
aOf the parous patients
Table 2 Tumor characteristics of the AI-treated patients with ER+ tumors included in the DMET™ chip analysis and the extended
cohort
Patients included in the analysis of the
DMET™ chip
Patients in the extended cohort included in the
survival analyses
n = 24 n = 201
Number (%) Missing Number (%) Missing
Invasive tumor size, mm (stage) 0 0
≤20 (pT1) 15 (62.5 %) 128 (63.7 %)
21–50 (pT2) 8 (33.3 %) 69 (34.3 %)
51–(pT3) 1 (4.2 %) 4 (2.0 %)
Skin or muscular involvement (pT4) 0 (0 %) 0 (0 %)
≥21 mm or skin or muscular involvement 9 (37.5 %) 73 (36.3 %)
Axillary node involvement 0 0
0 8 (33.3 %) 55 (27.4 %)
1–3 9 (37.5 %) 107 (53.2 %)
4+ 7 (29.2 %) 39 (19.4 %)
Any axillary lymph node 16 (66.7 %) 146 (72.6 %)
Histological grade 0 0
I 6 (25.0 %) 44 (21.9 %)
II 16 (66.7 %) 124 (61.7 %)
III 2 (8.3 %) 33 (16.4 %)
Hormone receptor status 0 0
ER+ 24 (100.0 %) 201 (100.0 %)
PgR+ 20 (83.3 %) 161 (80.1 %)
Simonsson et al. BMC Cancer  (2016) 16:256 Page 5 of 12
DMET™ chip in the 24 patients. The first CYP19A1
SNP, rs700518, appeared in 12th place (P = 0.014).
However, a special focus was placed on CYP19A1 in
this paper since aromatase is the target of AIs. There-
fore, five CYP19A1 SNPs (rs700518, rs4646, rs10046,
Aro1, and Aro2) were also selected for survival ana-
lyses in the extended cohort. Moreover, since AhR is
involved in the regulation of CYP1A2, genotyping was
also performed for two functional AhR SNPs Arg554Lys
(rs2066853) and Val570Ile (rs4986826) of which only
Arg554Lys was included in the DMET™ chip.
CYP1A2 rs762551 in relation to risk for early events in
AI-treated patients
The patients were followed for up to 11 years with a me-
dian follow-up time of 7.2 years (IQR 5.3–9.2) for pa-
tients who were alive and still at risk at the last follow-
up. The minor allele frequency (MAF) was 29.0 % for
CYP1A2 rs762551 (C-allele). AI-treated patients with ER
+ tumors and any C-allele of CYP1A2 rs762551 geno-
type (n = 103) had a significantly higher risk for early
breast cancer events versus the patients with A/A geno-
type (Fig. 2a; adjusted HR 2.22 (95 % CI 1.03–4.80). How-
ever, the main treatment predictive impact of CYP1A2
rs762551 was found within five years of inclusion (early
events), adjusted HR 7.88 (95 % CI 2.13–29.19).
When the patients ever treated with chemotherapy
were excluded as was done in the DMET™ analysis, 159
patients remained and 26 events occurred until 30th June
2014. Here, the association did not remain significant,
adjusted HR 1.97 (95 % CI 0.84–4.59) but a significant
impact was found within five years of inclusion, adjusted
HR 7.22 (95 % CI 1.49–40.00).
After exclusion of patients ever treated with tamoxifen
and/or chemotherapy, only 42 patients remained and 8
events occurred. The association was significant in the
univariable model (LogRank P = 0.002) and for events
within five years (P = 0.032). Due to small numbers, no
Cox regression was performed. The AI-treated patients
with ER+ tumors and any C-allele of CYP1A2 rs762551
also had a significantly increased risk for early distant
metastases overall (LogRank P = 0.020), adjusted HR
3.47 (95 % CI 1.26–9.56) and within five years (LogRank
P = 0.020), adjusted HR 7.80 (95 % CI 1.51–40.32).
Combination of CYP1A2 and AhR
Genotyping of the AhR SNP Val570Ile (rs4986826) was
non-informatory since all patients had the G/G
genotype. The minor allele frequency for Arg554Lys
(rs2066853 A-allele, Lys) was 11.9 %. There was no link-
age between the CYP1A2 rs762551 and AhR Arg554Lys
genotypes. AhR Arg554Lys was not associated with early
events in the patients included in the analysis of the
DMETTM chip and appeared in 524th place. However, in
the extended cohort, patients with any A-allele of the
AhR Arg554Lys had a significantly higher risk for early
events compared to patients with the G/G genotype
overall (LogRank P = 0.005), adjusted HR 2.61 (95 % CI
1.24–5.50) and within five years (LogRank P = 0.013),
adjusted HR 3.33 (95 % CI 1.24–8.96).
There was no interaction between the CYP1A2
rs762551 and AhR Arg554Lys. However, a combination
of the two SNPs showed multiplicative associations. Pa-
tients who had at least one minor allele in both genes,
i.e., any CYP1A2 C-allele and any AhR A-allele, had the
highest risk for early events followed by patients who
had a CYP1A2 A/A genotype and AhR any A-allele or
CYP1A2 any C-allele and AhR G/G compared to
patients who were homozygous for the major allele in
both genes CYP1A2 A/A and AhR G/G (LogRank 3 df;
P = 0.013), Fig. 3a. Since the curves for patients with
CYP1A2 A/A and AhR any A-allele or CYP1A2 any
C-allele and AhR G/G overlapped, these genotypes
were combined in the multivariable model into one
group of patients that were homozygous for the major
allele in one but not both genes. Overall, compared
to patients who were homozygous for the major allele
in both genes, patients who had at least one minor
allele in both genes (n = 20, 7 events) had a 9-fold risk for
early events, adjusted HR 8.95 (95 % CI 2.55–31.35),
whereas patients with at least one minor allele in one but
not both genes (n = 107, 19 events) had a 3-fold risk for
early events, adjusted HR 2.81 (95 % CI 1.07–7.33). These
results were also seen when the analysis was restricted to
the first five years (LogRank 3 df; P < 0.001), Fig. 3b.
CYP19A1 in relation to risk for early events in AI-treated
patients
The CYP19A1 SNP rs700518 was not successfully geno-
typed using iPlex and could not be further analyzed. The
MAF for rs4646 (A-allele), rs10046 (T-allele), Aro1 (T-
allele), and Aro2 (T-allele) were 30.8, 49.3, 47.0 and
40.0 %, respectively. In line with the DMET™ data, the
genotypes, haplotypes, and diplotypes of the four
CYP19A1 SNPs were not associated with early events
(all adjusted P-values > 0.10; see Fig. 2b for rs4646). Ex-
cluding the patients ever treated with chemotherapy
and/or tamoxifen did not materially change the result.
All of the results remained insignificant in relation to
risk for distant metastases.
Combination of CYP19A1 SNPs and CYP1A2
To investigate whether the findings regarding risk for
early events and the CYP1A2 rs762551 SNP were modi-
fied by the CYP19A1 SNPs, stratification according to
each genotype of the four CYP19A1 SNPs was
performed. No effect modification was observed be-
tween the strata for rs10046, Aro1, Aro2, and CYP1A2
Simonsson et al. BMC Cancer  (2016) 16:256 Page 6 of 12
rs762551. The interaction analyses were non-significant.
However, the interaction between CYP1A2 rs762551 any
C-allele and the C/C genotype of CYP19A1 rs4646 was
significant (adjusted Pinteraction = 0.022). Any C-allele car-
riers of CYP1A2 rs762551 with the C/C genotype of
CYP19A1 rs4646 (n = 48, 15 events) had over a 3-fold
increased risk of early events versus the rest of the AI-
treated patients (Fig. 2c-d; LogRank P = 0.001), adjusted
HR 3.39 (95 % CI 1.60–7.16). As with CYP1A2 rs762551
alone, the main treatment predictive impact of was found
within five years (LogRank P = 0.00001), adjusted HR
10.42 (95 % CI 3.45–31.51).
97 97 95 94 92 89 66 64 31 30 7








adjusted HR 2.22 (95% CI 1.03-4.80)
A/A
AnyC
Number of events:Number entering interval:
5-year LogRank P=0.006
5-year adjusted HR 7.88 
(95% CI 2.13-29.19)
104 104 102 100 96 92 68 66 38 35 8 5






adjusted HR 1.53 (95% CI 0.71-3.32)
Any A
C/C
Number of events:Number entering interval:
5-year LogRank P=0.046






LogRank 3df; P=0.013 
CYP1A2 & CYP19A1 
A/A & Any A
A/A & C/C
Any C & Any A
Any C & C/C
Any C & C/C
A/A & C/C
A/A & Any A
48 48 47 47 46 44 34 34 17 16 4
49 49 48 47 46 45 32 30 14 14 3 5
55 55 54 52 49 47 34 32 21 19 4








Any C & Any A
CYP1A2 rs762551 & CYP19A1 s4646 
Number of events:
152 152 149 146 141 136 100 96 52 49 11 8 17
48 48 43 40 33 30 21 21 14 12 5 2 15
Number entering interval:




adjusted HR 3.39 (95% CI 1.60-7.16)
5-year LogRank P=0.00001
5-year adjusted HR 10.42 
(95% CI 3.45-31.51)
A/A & Any A-allele or A/A & C/C or Any C-allele  &
Any C-allele & C/C






Fig. 2 a-d Kaplan-Meier estimates of event-free survival in relation to CYP1A2 and CYP19A1 genotypes in AI-treated breast cancer patients with
ER+ tumors are illustrated. LogRank P-values are presented for the entire follow-up time. In Fig. 2a, b, and d, 5-year adjusted HRs are also
presented. a CYP1A2 rs762551. The main association between CYP1A2 rs762551 any C-allele and early events was observed within 5 years of
inclusion. b CYP19A1 rs4646. No significant association between CYP19A1 rs4646 and early events was observed. c Combinations of CYP1A2
rs762551 and CYP19A1 rs4646 genotype. Patients with any C-allele of CYP1A2 rs762551 and C/C genotype of rs4646 had a worse prognosis
compared to patients with the three other genotype combinations. d CYP1A2 rs762551 any C-allele and rs4646 C/C. A combined variable of any
C-allele of CYP1A2 rs762551 and C/C genotype of rs4646 was created and patients with this combination had a worse prognosis compared to
patients with any other genotype. The main association was observed within 5 years of inclusion
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73 73 73 72 70 68 50 48 25 24 5 5
24 24 22 22 22 21 16 16 6 6 2 0
83 83 78 74 67 63 42 40 25 24 8 4
20 20 19 18 15 14 13 13 10 7 1 1
Number of events:
Number entering interval:
LogRank 3 df; P=0.013 
CYP1A2 & AhR 
A/A & G/G
A/A & Any A
Any C & G/G
Any C & Any A
Any C & Any A






Any C & G/G
CYP1A2 rs762551 & AhR Arg554Lys 
5-year LogRank 2 df; P<0.001
5-year adjusted HR 11.53 
(95% CI 1.41-94.47)
5-year adjusted HR 72.97 
(95% CI 6.85-777.0)
73 73 73 72 70 68 50 48 25 24 5 5
107 107 100 96 89 84 58 56 31 30 10 4
20 20 19 18 15 14 13 13 10 7 1 1
Number of events:
Number entering interval:
CYP1A2 & AhR 
A/A & G/G
A/A & Any A or
Any C & G/G
Any C & Any A
Any C & Any A





CYP1A2 rs762551& AhR Arg554Lys 
LogRank 2 df; P=0.009
adjusted HR 2.81 (95% CI 1.07-7.33)
adjusted HR 8.95 (95% CI 2.55-31.35)
a
b
Fig. 3 (See legend on next page.)
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Discussion
The present study investigated the association between
SNPs in ADME-related genes and the risk of early breast
cancer events in AI-treated patients with primary breast
cancer. The main finding was that CYP1A2 rs762551
was significantly associated with risk of early breast can-
cer events among AI-treated patients with ER+ tumors,
both in the exploratory analysis and in the extended co-
hort. This suggests that CYP1A2 rs762551 may be a pre-
dictive marker for early AI-response. To the best of our
knowledge, this has not been reported before.
The DMET™ chip was selected because the included
SNPs are involved in genes of importance for drug me-
tabolism and transportation. This approach increases the
chance that a finding is of biological relevance for AI re-
sponse. The cut-off for the P-value in the DMET™ ana-
lysis was chosen to allow for identification of potentially
new candidate genes while keeping the number of false
positive findings low. As this was an exploratory analysis
of nearly 2000 SNPs, a Bonferroni correction would have
been too stringent and the risk for false negative findings
substantial. The CYP1A2 rs762551 was the only SNP
that met the predetermined cut-off and the enzyme is
involved in the metabolic pathways of AIs or is inhibited
by AIs [25, 27, 28], which increases the chance that the
finding may be of biological relevance.
CYP1A2 is a phase I pathway for drug metabolism and
elimination [40]. An in vitro study reported a significant
role of CYP1A2 in exemestane metabolism [28]. More-
over, CYP1A2 catalyzes the conversion of estradiol to
hydroxylated metabolites, primarily 2-hydroxylated
estradiol [23], which has been shown to act as a weak or
even as an anti-estrogenic substance [41]. In a subset
of 59 patients in the current cohort, the CYP1A2
rs762551 C-allele was associated with a low 2OHE-to-
16alphaOHE1 plasma ratio both pre- and post-
operatively [42]. However, none of these patients were
treated with AIs at the time of blood draw. Since AIs
block estrogen formation, it is unlikely that there are
measurable estrogen metabolite plasma levels in the
201 AI-treated patients.
The CYP1A2 rs762551 is located in intron 1 of the
CYP1A2 gene and carries a -163C > A substitution.
CYP1A1/2 expression is regulated by the AhR and a
number of transcription factors and might be influenced
by transcriptional coactivators and corepressors [43].
The A/A genotype of CYP1A2 rs762551 is highly
inducible especially by smoking [44] and coffee con-
sumption [45]. Neither smoking nor coffee consumption
accounted for the association between CYP1A2, AhR,
and risk for early events (data not shown). Furthermore,
all multivariable models were adjusted for smoking.
While the CYP1A2 rs762551 has been shown to influ-
ence inducibility, it has not been shown to significantly
alter the gene expression [46]. The results are conflicting
as to whether the SNP influences CYP1A2 enzyme activ-
ity [43, 46]. Aklillu et al. have performed extensive
characterization of CYP1A2 genotype phenotype correla-
tions [47]. Cell transfection experiments showed that
there was no significant difference in the constitutive
transcriptional activity depending on the CYP1A2
rs762551 SNP. Further, electrophoretic mobility shift
assay analysis could not identify any specific transcrip-
tion factor whose binding could be affected by rs762551.
However, a xenobiotic response element (XRE) contain-
ing an invariant CACGC core sequence, recognized by
AhR, is present in CYP1A2 intron 1 further downstream
of the rs762551 site [47]. In the current study, a multi-
plicative association between having at least one
CYP1A2 rs762551 C-allele and at least one AhR
Arg554Lys A-allele on the risk for early events in AI-
treated patients was observed. Helmig et al. reported
that the AhR A-allele (Lys) confers lower expression of
AhR compared to the G-allele (Arg) [48]. Further, there
is cross-talk between AhR and ERα. An animal rat
model showed that ligand-activated AhR confers anti-
estrogenic effects partly due to lower ERα levels in
ductal epithelial cells [49]. CYP1A2 is mainly expressed
in liver cells but has also been detected in the ER+ breast
cancer MCF-7 cell-line after induction [30]. In the current
study, neither AhR nor CYP1A2 were associated with
prognosis among the patients with ER+ tumors who had
not been treated with AIs but either received tamoxifen or
no endocrine treatment (data not shown). This suggests
that the association of AhR Arg554Lys and CYP1A2
rs762551 on prognosis may be exclusive for the AI-treated
patients where the ER is still open as opposed to
tamoxifen-treated patients where the ER is blocked. The
cross-talk between AhR and ER signaling may be one
mechanism behind these findings. Taken together, this
(See figure on previous page.)
Fig. 3 a Combinations of CYP1A2 rs762551 and Ahr Arg554Lys genotype. Patients with any C-allele of CYP1A2 rs762551 and any A-allele of AhR
Arg554Lys had a worse prognosis followed by patients with at least one minor allele in either but not both genes and the lowest risk was seen
in patients with the CYP1A2 rs762551 A/A genotype combined with the AhR Arg554Lys G/G genotype. b Three combinations of CYP1A2 rs762551
and Ahr Arg554Lys genotype. Patients who had a CYP1A2 A/A genotype and AhR any A-allele or CYP1A2 any C-allele and AhR G/G genotype
were combined to one moderate risk group as the curves were similar in these groups. Patients with CYP1A2 rs762551 any C-allele and AhR
Arg554Lys any A-allele had the highest risk for early events, followed by the combined group, compared to patients with CYP1A2 rs762551 A/A
genotype and AhR Arg554Lys G/G genotype. Please note that there are fewer patients with longer follow-up times as this is an on-going cohort
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suggests that AhR G/G carries may have both lower ERα
levels and more effective CYP1A2 transcription and ex-
pression. This may be especially pronounced in patients
with the highly inducible CYP1A2 A/A genotype, since
AhR regulates CYP1A2 expression, thus leading to a lower
risk for early events during AI-treatment.
In addition to AhR, other cis- or trans acting loci may
also regulate CYP1A2 gene expression levels [50]. The
CYP1A2 enzyme activity level and gene expression is
clustered with CYP2C8, CYP2C9, and CYP3A4 [51].
Further, CYP1A2 share a common promoter with
CYP1A1 [29]. However, CYP1A1, CYP2C8, CYP2C9, and
CYP3A4 were not significant in the analysis based on
the DMET™ chip data, therefore no further analyses was
performed here.
While the role of CYP1A2 rs762551 with respect to
breast cancer risk seems weak or non-significant [52],
unless coffee consumption was taken into account
[34, 53]. A meta-analysis showed that the association
between the AhR Arg554Lys and breast cancer risk
differs between studies of women with different eth-
nicities, although the overall result was no association
[54]. The CYP1A2 rs762551 is associated with the
metabolism of several drugs and also with efficacy
and toxicity [43]. Although the mechanism behind
the finding of the present study is not fully under-
stood, the current study provides new insight into
how the CYP1A2 rs762551 combined with the func-
tional AhR Arg554Lys variant is linked to prognosis
in AI-treated breast cancer patients. Moreover, AhR
appears to be involved in the regulation of CYP19A1
both in ovarian and adrenocortical cells via different
mechanisms [55]. Further mechanistic and translational
studies of the AhR and CYP1A1/2 signaling pathway with
respect to CYP19A1 regulation and AI-response are there-
fore warranted.
In the present study, a special focus was placed on
CYP19A1 since aromatase is the target of AIs. However,
genotypes, haplotypes, and diplotypes of CYP19A1 SNPs
rs4646, rs10046, Aro1, and Aro2 were not significantly
associated with a risk of early breast cancer events in the
AI-treated patients. These results are in line with the re-
cent study by of Leyland-Jones et al. [11] that investi-
gated CYP19A1 tumor genotype data in relation to
endocrine treatment response in the BIG 1–98 trial, but
in contrast to a previous study on genomic CYP19A1 ge-
notypes regarding the risk of recurrence in AI-treated
patients [13]. In the recent abstract by Umamasheran et
al., an increased risk for breast cancer recurrence was
observed among 191 Indian letrozole-treated T/T
carriers of rs4646 [13]. As mentioned in the back-
ground, several SNPs in CYP19A1 have previously
been associated with AI response in neoadjuvant and
metastatic settings. The rs4646 is among the most
frequently studied SNPs. The A-allele has previously
been associated with longer time to progression in
the metastatic setting [20] but with poor response in
the neoadjuvant setting [22]. The differences may be
due to ethnicity, different study types, and small
study populations. Furthermore, different types of AIs
may yield different results. The majority of the pa-
tients included in the present study had received ana-
strozole. A recent study by Lunardi et al. reported no
association between plasma estrone concentrations
during treatment with letrozole and rs4646 or rs10046
[56]. Since circulating estrone levels may influence the risk
for early events in breast cancer, this is in line with the
findings of no significant association between these SNPs
and early events in the present study.
In the present study, there was a significant interaction
between CYP1A2 rs762551 and CYP19A1 rs4646 with a
high risk for breast cancer events, especially within five
years, among patients with any C-allele of CYP1A2
rs762551 and C/C-carriers of CYP19A1 rs4646. This
subgroup was quite small, and the results need to be
interpreted with caution. There was no linkage between
CYP19A1 rs4646 and AhR Arg554Lys that could explain
the results (data not shown). All findings in the present
study warrant validation, preferably within a randomized
clinical trial. In such a trial, it would be possible to
elucidate whether these genotypes are associated with
AI-response. If so, this could guide selection of endo-
crine treatment for more personalized medicine in the
clinical setting.
The Skåne University Hospital in Lund has a catch-
ment area that includes almost 300,000 inhabitants. This
study is population-based since patients with breast
cancer diagnoses are not referred to other hospitals for
surgery. The vast majority of the patients who are diag-
nosed in Lund are Swedes, but no data on ethnicity was
collected. Thus, studies with different study populations
are warranted. Since the subset of the cohort that was
analyzed with the DMET™ chip also was part of the ex-
tended cohort from which they originated, all findings
warrant validation in an independent cohort. Further,
the follow-up period was relatively short—patients with
ER+ tumors tend to relapse later [57]. Therefore, the
long-term effects of CYP1A2 rs762551 or CYP19A1
rs4646 could not be evaluated. However, the main im-
pact of these SNPs was observed during the 5-year
period when endocrine treatment is administered. This
suggests that these SNPs may be involved in primary ra-
ther than acquired resistance.
Conclusions
This study identified a new potential AI-treatment
predictive marker in CYP1A2 rs762551 for early
breast cancer events, and the results indicate that
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CYP1A2 rs762551 in combination with CYP19A1
rs4646 or AhR Arg554Lys may yield even better treat-
ment prediction. The results of the current study in-
dicate that CYP1A2 rs762551 and the AhR signaling
pathway merit further study for AI-response. If
confirmed, these results may provide a way to more
personalized medicine.
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